API-Anhui IPCKE Pharmaceutical Technology Development Co., Ltd

Doxapram hydrochloride monohydrate

Doxapram hydrochloride is a central nervous system stimulant that belongs to the category of central nervous system drugs. At low doses, it can stimulate the carotid and aortic chemoreceptors to reflexively excite the medullary respiratory and cardiovascular centers. Its respiratory excitation effect is stronger than that of nicotinamide, and at high doses it can stimulate the spinal cord and brainstem, but it seems to have no effect on the cerebral cortex. In addition, it has a mild excitatory effect on the cardiovascular system, causing a slight increase in pulse rate, increased cardiac output, and mild elevation of blood pressure. The safety range of Doxapram hydrochloride is wide (i.e., the range between excitatory and convulsive doses is large), and it can be used as a substitute for tetracycline, nicotinamide, pentylenetetrazol, etc. Used for respiratory depression caused by central inhibitory drugs, acute respiratory failure caused by other reasons, COPD complicated with acute respiratory failure, and accelerated recovery after anesthesia surgery.

Tenapanor Hydrochloride

Tenapanor Hydrochloride is an oral sodium/hydrogen exchanger 3 (NHE3) inhibitor and a novel phosphate lowering drug. The kidney, as a key organ regulating phosphate balance, cannot effectively excrete phosphate when its function is severely impaired, leading to hyperphosphatemia becoming a common problem in CKD patients, especially dialysis patients. Although phosphate binders are used for treatment, the blood phosphorus concentration of dialysis patients may still increase in the long term.Tenapanor as an NHE3 inhibitor, can reduce the intake of sodium in the intestine, create conditions that inhibit the tight junction of the gastrointestinal tract, reduce the absorption of phosphate, and thus lower blood phosphorus concentration.

Pivmecillinam Hydrochloride

Pivmecillinam Hydrochloride is a prodrug of methicillin, characterized by its oral availability and good absorption after oral administration. After oral absorption, it is rapidly hydrolyzed into methicillin by esterase in the body, which binds to penicillin binding protein-2 (PBP-2) and interferes with bacterial cell wall biosynthesis, causing bacterial deformation and cell lysis, thereby exerting antibacterial effects. Clinically applied to urinary tract and respiratory tract infections, it can also be used for the treatment of typhoid fever. Pivmecillinam has stronger activity against gram-negative bacteria than gram-positive bacteria, and has stronger activity against Escherichia coli producing extended spectrum β - lactams (ESBLs). This drug has been on the market abroad for many years, is safe and effective, has a low resistance rate, and has advantages in pharmacoeconomics.

Aprocitentan

Aprocitentan is a dual endothelin A/B receptor (ETA/ETB) antagonist jointly developed and produced by Swiss company Idorsia and Johnson&Johnson. On March 19, 2024, Aprocitentan was approved for market by the US FDA. Aprocitentan is a novel oral antihypertensive drug that inhibits the binding of endothelin-1 (ET-1) to endothelin receptor A (ETA) and endothelin receptor B (ETB), blocking the harmful effects of endothelin-1 such as vasoconstriction, fibrosis, cell proliferation, and inflammation. Suitable for treating uncontrolled hypertension in patients with poor control of other treatments.

中文

Home/Product

Doxapram hydrochloride monohydrate

Tenapanor Hydrochloride

Pivmecillinam Hydrochloride

Aprocitentan